Journal of Current Oncology

COMMENTARY
Year
: 2019  |  Volume : 2  |  Issue : 1  |  Page : 19--21

Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer


Rohit Avinash Vadgaonkar, Kaustav Talapatra 
 Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Correspondence Address:
Dr. Kaustav Talapatra
Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Four Bungalows, Andheri (W), Mumbai 400 053
India

Borderline resectable pancreatic cancer (BRPC) is a clinically distinguished malignancy. With limited role of aggressive surgical intervention, neoadjuvant treatment is warranted. Various studies and their meta-analysis addressing this issue have shown limited benefit. However, recently two prospective multiple randomized trials have evaluated benefit of neoadjuvant chemoradiotherapy in BRPC with a positive clinical response. This article gives a brief insight into these studies and discusses future prospects for role of radiation in neoadjuvant setting in pancreatic cancer.


How to cite this article:
Vadgaonkar RA, Talapatra K. Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer.J Curr Oncol 2019;2:19-21


How to cite this URL:
Vadgaonkar RA, Talapatra K. Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer. J Curr Oncol [serial online] 2019 [cited 2024 Mar 28 ];2:19-21
Available from: http://www.https://journalofcurrentoncology.org//article.asp?issn=2589-8892;year=2019;volume=2;issue=1;spage=19;epage=21;aulast=Vadgaonkar;type=0